57
Participants
Start Date
October 31, 2005
Primary Completion Date
September 30, 2011
Study Completion Date
July 31, 2013
erlotinib
Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
Ohio State University, Columbus
Collaborators (1)
Genentech, Inc.
INDUSTRY
Ohio State University Comprehensive Cancer Center
OTHER